Kimberly Manhard sold $115k of INBX
director at Inhibrx Biosciences, Inc.. 1,000 shares at an average of $115.47, traded Sep 8, 2026, filed Sep 10, 2026.
Score components
- +15RoleDirector
- +10Trade size$115k at market
- +5Share of holdings soldSold 10% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001202094-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | SOpen-market sale Common Stockindirect: Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 | -500 | $115.14 | $58k | 9,500 | 34 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stockindirect: Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012 | -500 | $115.80 | $58k | 9,000 | 34 d ago |
Related signals
Other insiders at Inhibrx Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 63Notable | Inhibrx Biosciences, Inc. | Mark Lappe Chief Executive Officer | $999k 10,000 shares | +1% | |
| 46Moderate | Inhibrx Biosciences, Inc. | Jon Faiz Kayyem director | $500k 5,000 shares | +1% | |
| 53Moderate | Inhibrx Biosciences, Inc. | Jon Faiz Kayyem director | $500k 5,000 shares | +1% | |
| 31Weak | INBXsell Inhibrx Biosciences, Inc. | Kimberly Manhard director | $164k 1,500 shares | -17% | |
| 44Moderate | Inhibrx Biosciences, Inc. | Douglas Forsyth director | $287k 2,500 shares | +1% | |
| 65Notable | Inhibrx Biosciences, Inc. | Mark Lappe Chief Executive Officer | $2.6M 25,000 shares | +4% | |
| 49Moderate | Inhibrx Biosciences, Inc. | Jon Faiz Kayyem director | $568k 5,000 shares | +1% | |
| 42Moderate | INBXsell Inhibrx Biosciences, Inc. | Viking Global Investors LP owner | $11M 350,000 shares | -22% | |
| 50Moderate | INBXbuy Inhibrx Biosciences, Inc. | Jon Faiz Kayyem director | $1.5M 107,186 shares | +660% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.